Story thread · 2 reports / 2 sources
Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry
investors.com · 4h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. The post Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry appeared first on Investor's Business Daily .
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.